How to Interpret the Results of Japan Clinical Oncology Group 0802 Study, a Comparison between Lobectomy and Segmentectomy for the Peripheral Non-Small Cell Lung Cancer

Hisao Asamura (Keio Univ., Japan)

VOD

Ultrasensitive Detection of Minimal Residual Disease of Non-Small Cell Lung Cancer through Whole Genome Sequencing Using AI Based Error Suppression Model

Aaron Tan (National Cancer Centre Singapore, Singapore)

VOD

Novel Plasma Based Detection of Early Stage Lung Cancer

Eun-Hae Cho (GC genome)

VOD

Early Stage Lung Cancer Diagnosis by AI-Based Spectroscopic Analysis of Circulating Exosomes

Yeonho Choi (Korea Univ.)

VOD

Long-Term Surgical Outcomes of Oligometastatic Non-Small-Cell Lung Cancer: A Single-Center Study

Seungmo Yoo (University of Ulsan)

VOD

Existence of Pre-operative Clonal Hematopoiesis Is Related to Adverse Outcome in Surgically Resected Non-Small Cell Lung Cancer Patients Who Underwent Adjuvant Therapy

Jae Kwang Yun (University of Ulsan)

VOD

Longitudinal Monitoring of Circulating Tumor DNA from Plasma in Patients with Curative Resected Stage IA-IIIA EGFR Mutant-Non-Small Cell Lung Cancer

Hyun Ae Jung ( Sungkyunkwan University )

VOD

Risk Prediction of Multiple–station N2 Metastasis in Patients with Clinical Single–station N2 NSCLC

Joon Young Kim (University of Ulsan)

VOD

Different Prognostic Impact between Single-Zone and Multiple-Zone N2 Node Metastasis in Patients with N2b NSCLC

Shia Kim (University of Ulsan)

VOD

Lobectomy Versus Sublobar Resection for Stage I (T1-T2aN0M0) Small Cell Lung Cancer: A SEER Population-Based Propensity Score Matching Analysis

Ning Zhou (Tianjin Medical University)

VOD

Clinical Outcome of Stereotactic Body Radiotherapy in Early-Stage Lung Cancer Patient with Ground Glass Opacity Predominant Lesion: A Single Institution Experience

Jeong Yun Jang (University of Ulsan )

VOD

Oncologic Outcomes of Stereotactic Body Radiotherapy in Early-Stage Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease

Young Seob Shin (University of Ulsan)

VOD

Osimertinib and Durvalumab as Frontier Treatment for Non-Small Cell Lung Cancer Patients with Curative Intent

James Yang (National Taiwan Univ., Taiwan)

Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients from VISION Cohorts A and C

Myung-Ju Ahn (Sungkyunkwan University)

VOD

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer

Hyun Ae Jung (Sungkyunkwan University)

VOD

Evaluation of Blood Tumor Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial

Cheol-Kyu Park (Chonnam National University )

VOD

Distinct Characteristics and Treatment Outcomes of Exon20 Insertion Mutations Positive Non-Small Cell Lung Cancer Patients in Real World Practice

Mi Sook Kim (National Cancer Center​)

VOD

AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC

Se Hyun Kim (Seoul National University )

VOD

Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer

Jang Ho Lee (University of Ulsan)

VOD

Tepotinib in Asian Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping

Ji-Youn Han (National Cancer Center)

VOD

Application of Machine Learning Algorithms for the Prediction of Afatinib Treatment Outcome in Advanced Stage EGFR-Mutated NSCLC

Taeyun Kim (The Armed Forces Goyang Hospital)

VOD

AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab+Tislelizumab with Chemotherapy in Patients with Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer

Hye Ryun Kim (Yonsei University)

VOD

Clinical Response to Tepotinib according to Circulating Tumor (ct)DNA Biomarkers in Patients with Advanced NSCLC with High-Level MET Amplification

Jin-Hyoung Kang (The Catholic University of Korea)

VOD

Ablative Treatment for Limited Metastatic Lung Cancer: Past Lessons and Future Directions

Daniel R. Gomez (MSKCC, USA)

Integrating SBRT into the Treatment of Oligometastatic Non-Small Cell Lung Cancer with Actionable Mutations: Now and the Future

Oscar S.H. Chan (Hong Kong Integrated Oncology Centre, Hong Kong)

VOD

Advanced Radiotherapy Techniques for Oligometastatic Lung Cancer and A Pattern of Care Survey within Korean Radiation Oncologists

Yang-Gun Suh (National Cancer Center)

VOD

Role of Surgery in Oligometastatic Lung Cancer

Seong Yong Park (Sungkyunkwan Univ.)

VOD

Timing of Local Consolidative Therapy in Oligometastatic Non-Small Cell Lung Cancer: Upfront or Later?

Jeong Uk Lim (The Catholic Univ. of Korea)

VOD

The Indispensable Treatment Option for More TOMORROWs: Pembrolizumab for Metastatic Non–Small Cell Lung Cancer Patients in the First-Line

Beung-Chul Ahn (National Cancer Center)

Implementation of Population Based Lung Cancer Screening in Europe

John K. Field (The Univ. of Liverpool, UK)

VOD

Lung Cancer Screening in Never-Smokers

Ryutaro Kakinuma (E-medical Tokyo, Japan)

VOD

Functional Genomics Approaches to Understand Genetic Susceptibility to Lung Cancer

Jiyeon Choi (National Cancer Institute, USA)

VOD

Radiologic Characteristics of Multiple Primary Lung Cancer Including Ground Glass Nodules

Geewon Lee (Pusan National Univ.)

VOD

Pathologic Differentiation and Significance of Next-Generation Sequencing for Synchronous or Metachronous Lesions vs Metastatic or Recurred Lesions in Lung Cancer

Jin-Haeng Chung (Seoul National Univ.)

VOD

Surgical Strategy for Multiple Primary Lung Cancer

Alan D. L. Sihoe (Gleneagles Hong Kong Hospital, Hong Kong)

VOD

Recent Advances in Radiotherapy for Multiple Primary Lung Cancer

Si Yeol Song (Univ. of Ulsan)

VOD

Osimertinib and Durvalumab as Frontier Treatment for Non-Small Cell Lung Cancer Patients with Curative Intent

James Yang (National Taiwan Univ., Taiwan)

Lung Cancer Genomic Evolution during the Establishment and Propagation of Patient-Derived Xenograft Models

Robert E. Hynds (Univ. College London, UK)

VOD

A Minimal Sufficient Condition for the Development of K-Ras-Activated Lung Cancer

Suk-Chul Bae(Chungbuk National Univ.)

VOD

Development of a Novel Mouse Model for Improved Evaluation of in vivo Anti-Cancer Effects: Targeted Therapy and Immunotherapy

Jin Kyung Rho (Univ. of Ulsan)

VOD

Clinical Application of Natural Killer T Cells to Cancer Immunotherapy

Shinichiro Motohashi (Chiba Univ., Japan)

VOD

Potential Role of Non-Genetically Modified Natural Killer Cells with Enhanced Cytotoxicity in Combination with either Immune Checkpoint Inhibitors or Anti-tumor Monoclonal Antibodies in Lung Cancer

Paul Y. Song (NKgene Biotec, USA)

VOD

Engineered Canner Immune Cell Therapy (CAR-T Cell Therapy)

Hun Ju Lee (UT MD Anderson Cancer Center,USA)

VOD

The Evolving Treatment Landscape of ALK+Non-Small Cell Lung Cancer with Lorlatinib

Sehhoon Park (Sungkyunkwan Univ.)

The Reimbursement Decision Process of Anticancer Agents in Korea

Kook Hee Kim (HIRA)

VOD

The Current Reimbursement Status of Lung Cancer Treating Agents in Korea

Dong-Wan Kim (Seoul National Univ.)

VOD

Role of Companion Diagnostics in Anticancer Drug Reimbursement Decision

Yoon La Choi (Sungkyunkwan Univ.)

VOD

Panel Discussion

Panel: Speakers / Ji-Youn Han (National Cancer Center) / Dae Ho Lee (Univ. of Ulsan) / Sung-Yong Lee (Korea Univ.)

Introduction of National Health Insurance Service (NHIS) Big Data

Young-Eun Kim (National Health Insurance Service)

VOD

Clinical Research Using NHIS Big Data: Present and Future

Jaehun Jung (Gachon Univ.)

VOD

Introduction of Lung Cancer Fact Sheet Project

Wonjun Ji (Univ. of Ulsan)

VOD

Osimertinib and Durvalumab as Frontier Treatment for Non-Small Cell Lung Cancer Patients with Curative Intent

James Yang (National Taiwan Univ., Taiwan)

Metastatic Non-Small Cell Lung Cancer: How Can We Improve Immunotherapy in Metastatic Disease

Herbert H. Loong (The Chinese Univ. of Hong Kong, Hong Kong)

VOD

Locally Advanced Non-Small Cell Lung Cancer: Who Benefits from Immunotherapy with Definitive Chemoradiotherapy

Hyun Ae Jung (Sungkyunkwan Univ.)

VOD

Early Non-Small Cell Lung Cancer: Where Is Immunotherapy after Curative Surgery

Min Hee Hong (Yonsei Univ.)

VOD

Updates of Immunotherapy in Thymic Cancers and Mesothelioma

Yong Won Choi (Ajou Univ.)

VOD

Frontline Immunotherapy in Extensive Stage Small Cell Lung Cancer

Hye Ryun Kim (Yonsei Univ.)

VOD

Existing Treatment Options and Future Directions for Second Line and beyond in Extensive Stage Small Cell Lung Cancer

Vivek Subbiah (UT MD Anderson Cancer Center, USA)

VOD

Role of Thoracic Radiotherapy Extensive Stage Small Cell Lung Cancer

Jae Myoung Noh (Sungkyunkwan Univ.)

VOD

A New Era of Treatment Opportunities for Metastatic Non-Small Cell Lung Cancer Patients : First-in-Class RET Inhibitor “Retevmo”

Kaname Nosaki (National Cancer Center Hospital East, Japan)